Experimental chikungunya vaccine induces robust antibody response

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of The Lancet.

Experimental chikungunya vaccine induces robust antibody response

Read more View All News

This page was last updated on Friday, January 21, 2022